| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 144.21▼ | 144.64▼ | 144.37▼ | 139.86▲ | 143.37▲ |
| MA10 | 144.34▼ | 144.15▼ | 142.94▲ | 142.51▲ | 133.08▲ |
| MA20 | 144.64▼ | 142.72▲ | 140.34▲ | 143.78▲ | 112.26▲ |
| MA50 | 144.35▼ | 139.17▲ | 141.39▲ | 128.87▲ | 88.78▲ |
| MA100 | 143.01▲ | 141.58▲ | 142.91▲ | 107.57▲ | 67.19▲ |
| MA200 | 140.70▲ | 143.14▲ | 140.53▲ | 90.82▲ | 44.43▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.109▼ | 0.024▲ | 0.666▲ | -1.574▼ | 2.784▲ |
| RSI | 40.653▼ | 63.100▲ | 62.177▲ | 59.946▲ | 76.525▲ |
| STOCH | 25.404 | 77.906 | 88.136▲ | 43.509 | 90.363▲ |
| WILL %R | -91.743▼ | -23.303▲ | -16.560▲ | -29.627 | -9.377▲ |
| CCI | -154.399▼ | 40.323 | 75.172 | 11.257 | 75.068 |
| MA | $INSM Price Crossed Above MA(13) | Set Alert |
|
Tuesday, September 30, 2025 11:33 AM
Brinsupri FDA approval, with strong sales potential and M&A interest. Click here to find out why INSM stock is a Buy.
|
|
Tuesday, September 30, 2025 09:32 AM
Financially, the business reported Q2 2025 revenues of $107.4 million for ARIKAYCE, up 19% year-over-year, with a strong gross margin of 75.7%, despite a net loss of $321.7 million. The company also ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 30/09/25 | 141.63 | 145.41 | 141.00 | 144.01 | 2,654,255 |
| 29/09/25 | 137.19 | 141.81 | 136.62 | 141.65 | 2,564,031 |
| 26/09/25 | 136.86 | 137.04 | 134.01 | 137.03 | 1,389,737 |
| 25/09/25 | 140.55 | 140.65 | 135.08 | 135.59 | 2,168,769 |
| 24/09/25 | 144.97 | 145.56 | 140.87 | 141.00 | 1,455,591 |
| 23/09/25 | 144.71 | 146.29 | 143.83 | 145.38 | 1,610,390 |
| 22/09/25 | 144.76 | 146.71 | 144.03 | 145.03 | 2,896,264 |
| 19/09/25 | 145.51 | 146.37 | 142.88 | 144.76 | 5,624,088 |
| 18/09/25 | 144.76 | 146.50 | 143.82 | 145.86 | 1,835,993 |
| 17/09/25 | 145.90 | 146.50 | 143.765 | 144.78 | 1,728,316 |
|
|
||||
|
|
||||
|
|